(Q39633289)

English

Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels.

scientific article published on 11 November 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21069318%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21069318%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

based on heuristic

inferred from title

Vladimir Tolmachev

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21069318%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21069318%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

author name string

Helena Wållberg

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21069318%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Mattias Sandström

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21069318%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Monika Hansson

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21069318%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Anders Wennborg

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21069318%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

publication date

11 November 2010

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21069318%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

number of pages

9

1 reference

based on heuristic

inferred from page(s)

European Journal of Nuclear Medicine and Molecular Imaging

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21069318%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

38

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21069318%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21069318%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

531-539

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21069318%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

https://scigraph.springernature.com/pub.10.1007/s00259-010-1646-3

0 references

EGF-ERBB signalling: towards the systems level

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1646-3

21 January 2018

Trastuzumab: triumphs and tribulations

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1646-3

21 January 2018

Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: antiproliferative activity on human breast carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1646-3

21 January 2018

[(177)Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1646-3

21 January 2018

Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1646-3

21 January 2018

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1646-3

21 January 2018

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1646-3

21 January 2018

Tumor markers in breast cancer- European Group on Tumor Markers recommendations.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1646-3

21 January 2018

Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1646-3

21 January 2018

HER-2/neu expression in primary and metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1646-3

21 January 2018

Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1646-3

21 January 2018

Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1646-3

21 January 2018

Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1646-3

21 January 2018

Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1646-3

21 January 2018

Site-specifically conjugated anti-HER2 Affibody molecules as one-step reagents for target expression analyses on cells and xenograft samples

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1646-3

21 January 2018

Radiolabelling DOTA-peptides with 68Ga

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1646-3

21 January 2018

Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1646-3

21 January 2018

Re: controversies--[Tc(CO)3]+ chemistry: a promising new concept for SPET?

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1646-3

21 January 2018

A facile, water-soluble method for modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1646-3

21 January 2018

The importance of high specific radioactivity in the performance of 68Ga-labeled peptide

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1646-3

21 January 2018

Biodistribution of 111in-DTPA-D-Phe1-octreotide in tumor-bearing nude mice: influence of amount injected and route of administration

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1646-3

21 January 2018

Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-Z EGFR:2377 Affibody molecule: aspect of the injected tracer amount

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1646-3

21 January 2018

In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours--impact of peptide mass

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1646-3

21 January 2018

Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1646-3

21 January 2018

Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1646-3

21 January 2018

Small-animal PET imaging of human epidermal growth factor receptor type 2 expression with site-specific 18F-labeled protein scaffold molecules

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1646-3

21 January 2018

[18F]FBEM-Z(HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1646-3

21 January 2018

Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and (18)F-labeled affibody molecules

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1646-3

21 January 2018

The role of model-based methods in the development of single scan techniques

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1646-3

21 January 2018

Quantitative analysis of PET studies

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1646-3

21 January 2018

Slow internalization of anti-HER2 synthetic affibody monomer 111In-DOTA-ZHER2:342-pep2: implications for development of labeled tracers.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1646-3

21 January 2018

Targeted therapy in breast cancer: the HER-2/neu gene and protein

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1646-3

21 January 2018

Peptide receptor imaging and therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21069318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The neu-oncogene product in serum and tissue of patients with breast carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/21069318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21069318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/21069318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/21069318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The achilles heel of ErbB-2/HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological intervention.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21069318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review

1 reference

https://pubmed.ncbi.nlm.nih.gov/21069318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastasic prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21069318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of dose and specific activity on tissue distribution of indium-111-pentetreotide in rats.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21069318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

GRP receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a 68Ga-labeled bombesin(6-14) analog

1 reference

https://pubmed.ncbi.nlm.nih.gov/21069318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Clinical study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21069318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumour uptake of the radiolabelled somatostatin analogue [DOTA0, TYR3]octreotide is dependent on the peptide amount

1 reference

https://pubmed.ncbi.nlm.nih.gov/21069318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules

1 reference

https://pubmed.ncbi.nlm.nih.gov/21069318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00259-010-1646-3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21069318%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21069318%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39633289&oldid=1802405639"